Literature DB >> 18243841

Patient-specific radiation dosimetry for radionuclide therapy of liver tumors with intrahepatic artery rhenium-188 lipiodol.

Pat B Zanzonico1, Chaitanya Divgi.   

Abstract

A clinically practical algorithm has been developed for the treatment of liver cancer by the administration of rhenium-188 ((188)Re)-labeled lipiodol via the hepatic artery. This algorithm is based on the "maximum tolerated-activity" paradigm for radionuclide therapy. A small "scout" activity of (188)Re-labeled lipiodol is administered to the patient before the actual therapeutic administration. At approximately 3 hours after administration, the activities in the normal liver, liver tumors, lungs, and total body are measured by gamma camera imaging using the conjugate-view method, with first-order corrections for attenuation (using a (188)Re transmission scan) and scatter (using the "dual-window" method). At the same time, peripheral blood samples are counted, and the activity concentrations in whole blood are calculated. The blood activity concentrations are then converted to red marrow activity concentrations and then total red marrow activity using anatomic data from Standard Man anthropomorphic models. Next, the cumulated activities in the normal liver, liver tumors, lungs, red marrow, and total body are calculated using the measured activities in the respective source regions and conservatively assuming elimination of activity only by physical decay in situ. The absorbed doses to the therapy-limiting normal tissues, liver, lung, and red marrow, are then calculated using the Medical Internal Radiation Dose Committee schema, adjusting the pertinent S factors for differences in total body and organ masses between the patient and the anthropomorphic model and including the dose contribution from the liver tumors. Finally, based on maximum tolerated absorbed doses of 3,000, 1,200, and 150 rad (cGy) to liver, lung, and red marrow, the respective absorbed doses per unit administered activity are used to calculate the therapy activity. Although not required for treatment planning, tumor absorbed dose may also be estimated. This algorithm has been automated using an Excel (Microsoft, Redmond, WA) spreadsheet.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18243841     DOI: 10.1053/j.semnuclmed.2007.10.005

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  4 in total

1.  Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization.

Authors:  Kostas Delaunay; Julien Edeline; Yan Rolland; Nicolas Lepareur; Sophie Laffont; Xavier Palard; Christelle Bouvry; Samuel Le Sourd; Marc Pracht; Valérie Ardisson; Nicolas Noiret; Éric Bellissant; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-02-04       Impact factor: 9.236

2.  Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals.

Authors:  Jill Wevrett; Andrew Fenwick; James Scuffham; Lena Johansson; Jonathan Gear; Susanne Schlögl; Marcel Segbers; Katarina Sjögreen-Gleisner; Pavel Solný; Michael Lassmann; Jill Tipping; Andrew Nisbet
Journal:  EJNMMI Phys       Date:  2018-08-02

3.  Biodistribution, pharmacokinetics, and organ-level dosimetry for 188Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scans.

Authors:  Pedro L Esquinas; Ajit Shinto; Koramadai K Kamaleshwaran; Jephy Joseph; Anna Celler
Journal:  EJNMMI Phys       Date:  2018-12-07

4.  Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma.

Authors:  Yong Du; Angel Cortez; Anders Josefsson; Mohammadreza Zarisfi; Rebecca Krimins; Eleni Liapi; Jessie R Nedrow
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.